Resources
About Us
Home Report
Store
Pharmacogenomics Market
Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) – Global Forecast to 2031
Report ID:MRHC - 104682 Pages: 210 Mar-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Pharmacogenomics Market was valued at $9.94 billion in 2023. This market is expected to reach $19.5 billion by 2031, from an estimated $10.74 billion in 2024, at a CAGR of 8.9% during the forecast period 2024-2031.
Pharmacogenomics Market Size & Forecast
The pharmacogenomics market is driven by the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA’s and EMA’s recommendations for using pharmacogenomic data in drug discovery & development. However, the high costs of personalized medicines restrain the growth of this market.
Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market. However, low awareness about pharmacogenomics and personalized medicine, the limited understanding of genetic testing and its benefits, and the lack of reimbursements for genetic testing and precision medicine are major challenges impacting market growth.
Increasing Adoption of Personalized Medicine Drives the Growth of the Pharmacogenomics Market
Precision medicine is an emerging approach to patient care. Physicians choose a treatment method based on the patient's genetic makeup (including genetic changes resulting from a disease) and lifestyle habits. It is an emerging disease treatment and prevention approach that considers individual variability in genes, environment, and lifestyle. Precision medicine can remove the need for guesswork, variable diagnostic ability, and treatment strategies based on generalized demographics. Moreover, precision medicine enables a more holistic view of an individual patient. Precision medicine for clinical workflow helps facilitate more predictive and preventive care through targeted therapies.
Some of the major advantages of precision medicine are reduction of trial & error prescription, avoidance of adverse drug reactions, increase in patient adherence to treatment due to fewer side effects, decrease in the unnecessary prescription of drugs to non-responder patients, optimization of drug development cost, control on healthcare cost, the revival of once failed drugs for use in a genetically defined population, and improvement in the quality of life of the patients.
Furthermore, precision medicine makes decisions based on individual-specific factors that affect their health. With precision, medical providers can customize each patient's customized treatment methodology, improving the probability of recovery. Readmissions can be eliminated, and preventive measures can be taken against a disease with the help of precision medicine.
Increasing Geriatric Population Drives the Market Growth
Older people aged 65 and above tend to have a higher prevalence of chronic conditions and other diseases due to declined immune functions. The rising geriatric population globally is consequently resulting in the increasing prevalence of chronic conditions, driving the growth of the pharmacogenomics market. According to the World Health Organization (WHO), the population of individuals ages 60 years or above is estimated to increase to 1.4 billion by 2030 compared to 1 billion in 2020. By 2050, the world’s population of people aged 60 years and older is likely to reach 2.1 billion.
Older people are more susceptible to treatment failures and adverse drug reactions (ADRs). Pharmacogenomics enables the screening of ADRs and the tailoring of personalized medicine regimes based on the individual’s genetic variation. The identification of drug-gene interaction allows individualized therapy. In addition, several pharmacogenomic findings have been reported for chronic conditions such as cardiovascular diseases, cancer, and neurological disorders commonly found in the elderly. Therefore, the rising geriatric is expected to drive the pharmacogenomics market in the coming years.
Key Findings of the Global Pharmacogenomics Market Study:
Consumables Segment to Dominate the Pharmacogenomics Market
The largest market share of this segment is attributed to the recurrent use of consumables over instruments and the high burden of chronic diseases. Moreover, the high increasing prevalence of chronic diseases coupled with the focus of players for the launch of advanced and better reagents & kits drives the segment growth.
Click here to: Get Free Sample Pages of this Report
Polymerase Chain Reaction Segment to Dominate the Pharmacogenomics Market
The large market share of this segment is attributed to the high sensitivity, accuracy, low sample volume requirements, and cost-effectiveness coupled with the high presence of PCR base across all the end users and initiatives by players to launch and get approvals for new PCR products for pharmacogenomics. Furthermore, key players are taking up several strategies, such as product launches and approvals supporting market growth. For instance, in March 2023, Bio-Rad Laboratories launched PTC Tempo 96 and PTC Tempo Deepwell Thermal Cyclers to optimize various PCR applications such as sequencing, cloning, and genotyping.
Oncology Segment is Expected to Dominate the Pharmacogenomics Market
The large market share of this segment is attributed to the high prevalence of cancer globally, the increasing adoption of precision medicine for cancer, and the benefits offered by pharmacogenomics in precision oncology. Cancer is one of the leading causes of global morbidity and mortality; failed treatment often results in death in patients. Pharmacogenomics offers insights into patients’ genetic response toward cancer treatment, which helps determine the proper course of treatment for the patient based on their genetic makeup. This increases the chance of rendering the treatment effective compared to trial-and-error approaches or conventionally used generalized treatments.
Hospitals & Diagnostic Laboratories Segment to Dominate the Pharmacogenomics Market
The large market share of this segment is attributed to the preference given to hospitals for the diagnosis and treatment of diseases, the presence of certified healthcare practitioners, and the expansion of molecular diagnostics capabilities in hospitals in response to the COVID-19 pandemic. The penetration of molecular diagnostic tools in hospitals accelerated due to the COVID-19 pandemic, along with increased acceptance and awareness of advanced technologies, such as NGS, among physicians. Moreover, the growing adoption of precision medicine, the growing prevalence of chronic diseases, and the focus on pharmacogenomic testing services companies’ acquisitions and launches of pharmacogenomic testing services also contribute to large segment share.
Asia Pacific: Fastest Growing Market
In 2024, North America is expected to account for the largest share of the global pharmacogenomics market. However, Asia-Pacific is slated to register the highest CAGR during the forecast period. Rising government spending to increase testing capacities; increasing cases of inherited diseases such as Down Syndrome, cystic fibrosis, sickle cell disease, colon (colorectal) cancer, and breast cancer; growing awareness about the significance of genetic tests; and increasing government initiatives promoting genetic testing contribute to the growth of the market.
Pharmacogenomics Market: Key Companies
The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments in leading industry market players over the past years. The key players operating in the global pharmacogenomics Market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).
Pharmacogenomics Market Report Summary:
|
Particular |
Details |
|
Page No |
210 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
8.9% |
|
Market Size (Value) |
$19.5 billion by 2031 |
|
Segments Covered |
By Offering
By Technology
By Application
By End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of APAC), Latin America, and Middle East & Africa |
|
Key Companies |
F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.). |
Key questions answered in the report:
The pharmacogenomics market covers the market sizes & forecasts of offerings, including consumables, instruments, and software & services. The pharmacogenomics market studied in this report involves the value analysis of various segments and sub-segments of the pharmacogenomics market at regional and country levels.
The global pharmacogenomics market is projected to reach $19.5 billion by 2031, at a CAGR of 8.9% during the forecast period.
Based on the application, in 2024, the oncology segment is expected to account for the largest share of the pharmacogenomics market due to the rising need for more targeted approaches, benefits offered by pharmacogenomics, such as the ability to predict cancer susceptibility, tumor progression & recurrence, patient survival, and response and toxicity to chemotherapy.
Which technology segment is projected to create more traction in the global pharmacogenomics market?
Based on the technology, the sequencing segment is projected to create more traction as the benefits provided by the newer technologies, such as next-generation sequencing (NGS), which include less turnaround time, multiple sample analysis in a single run, and a single system required for running a sample-to-the-end analysis.
The pharmacogenomics market is driven by the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA’s and EMA’s recommendations for using pharmacogenomic data in drug discovery & development. Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market.
The key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), OPKO Health, Inc. (U.S.), Dynamic DNA Laboratories (U.S.), Admera Health (U.S.), Qiagen N.V. (Netherlands), and Myriad Genetics, Inc. (U.S.).
Asia-Pacific is projected to offer significant growth opportunities for the vendors in this market due to factors such as the increasing prevalence of infectious & chronic diseases, supporting government initiatives, and rising healthcare expenditure.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process Of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from The Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions For the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Growing Therapeutic Applications of Pharmacogenomic Biomarkers Supporting Market Growth
4.2.1.2. Increasing Adoption of Personalized Medicines Driving the Demand for Pharmacogenomics
4.2.1.3. Rising Geriatric Population and Chronic Disease Prevalence Boosting Pharmacogenomic Research and Testing
4.2.1.4. The U.S. FDA’s And EMA’s Recommendations for Using Pharmacogenomic Data in Drug Discovery & Development Accelerating Market Expansion
4.2.1.5. Growing Awareness Regarding Adverse Drug Reactions (ADRs) Generating Opportunities for Market Players
4.2.1.6. Low Awareness About Pharmacogenomics and Personalized Medicine to Remain a Major Challenge for Market Stakeholders
4.2.1.7. Lack Of Reimbursements for Genetic Testing and Precision Medicine Impacting Market Growth
4.2.2. Factors Analysis
4.3. Key Trends
4.3.1. Declining Costs of Sequencing Making Pharmacogenomic Testing More Affordable
4.3.2. Increasing Potential of AI In Pharmacogenomics
4.4. Regulatory Analysis
4.4.1. U.S
4.4.2. Canada
4.4.3. Europe
4.4.4. China
4.4.5. Japan
4.4.6. India
4.4.7. Latin America
4.4.8. Middle East & Africa
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Degree Of Competition
5. Pharmacogenomics Market Assessment—by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software & Services
6. Pharmacogenomics Market Assessment—by Technology
6.1. Overview
6.2. Polymerase Chain Reaction (PCR)
6.3. Sequencing
6.4. Microarray
6.5. Mass Spectrometry
6.6. Electrophoresis
6.7. Other Technologies
7. Global Pharmacogenomics Market Assessment—by Application
7.1. Overview
7.2. Oncology
7.3. Mental Health
7.4. Infectious Diseases
7.5. Cardiology
7.6. Neurological Disorders
7.7. Other Applications
8. Pharmacogenomics Market Assessment—by End User
8.1. Overview
8.2. Hospitals & Diagnostic Laboratories
8.3. Academic & Research Institutes
8.4. Other End Users
9. Pharmacogenomics Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest Of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest Of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Ranking (2023)
10.5.1. Thermo Fisher Scientific, Inc. (U.S.)
10.5.2. Illumina, Inc. (U.S.)
10.5.3. Danaher Corporation (U.S.)
10.5.4. F. Hoffmann-La Roche Ltd. (Switzerland)
11. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
11.1. F. Hoffmann La-Roche Ag
11.2. Thermo Fisher Scientific, Inc.
11.3. Illumina, Inc.
11.4. Danaher Corporation
11.5. Agilent Technologies, Inc.
11.6. Qiagen N.V.
11.7. Abbott Laboratories
11.8. Bio-Rad Laboratories, Inc.
11.9. PerkinElmer, Inc.
11.10. Pacific Biosciences of California, Inc.
(Note: SWOT Analysis of Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Pharmacogenomics Instruments: Pricing
Table 2 Global Pharmacogenomics Market, by Offering, 2022—2031 (USD Million)
Table 3 Global Pharmacogenomic Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Pharmacogenomic Instruments Market, by Country/Region, 2022—2031 (USD Million)
Table 5 Global Pharmacogenomic Software & Services Market, by Country/Region, 2022—2031 (USD Million)
Table 6 Advantages and Disadvantages of Technologies for Pharmacogenomics
Table 7 Global Pharmacogenomics Market, by Technology, 2022—2031 (USD Million)
Table 8 Global Pharmacogenomics Market for Polymerase Chain Reaction, by Country/Region, 2022—2031 (USD Million)
Table 9 Global Pharmacogenomics Market for Sequencing, by Country/Region, 2022—2031 (USD Million)
Table 10 Global Pharmacogenomics Market for Microarrays, by Country/Region, 2022—2031 (USD Million)
Table 11 Global Pharmacogenomics Market for Mass Spectrometry, by Country/Region, 2022—2031 (USD Million)
Table 12 Global Pharmacogenomics Market for Electrophoresis, by Country/Region, 2022—2031 (USD Million)
Table 13 Global Pharmacogenomics Market for Other Technologies, by Country/Region, 2022-2031 (USD Million)
Table 14 Global Pharmacogenomics Market, by Application, 2022—2031 (USD Million)
Table 15 Number of New Cancer Cases, by Region, 2020 Vs. 2040 (In Million)
Table 16 Global Pharmacogenomics Market for Oncology, by Country/Region, 2022-2031 (USD Million)
Table 17 Global Pharmacogenomics Market for Mental Health, by Country/Region, 2022-2031 (USD Million)
Table 18 HIV Statistics (2021)
Table 19 Global Pharmacogenomics Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
Table 20 Global Pharmacogenomics Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
Table 21 Global Pharmacogenomics Market for Neurological Disorders, by Country/Region, 2022-2031 (USD Million)
Table 22 Global Pharmacogenomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
Table 23 Global Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 24 Global Pharmacogenomics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 25 Global Pharmacogenomics Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Pharmacogenomics Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Pharmacogenomics Market, by Country/Region, 2022–2031 (USD Million)
Table 28 North America: Pharmacogenomics Market, by Country, 2022–2031 (USD Million)
Table 29 North America: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 30 North America: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 31 North America: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 32 North America: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 33 U.S.: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 34 U.S.: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 35 U.S.: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 36 U.S.: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 37 Canada: Diabetes Prevalence 2023 Vs 2033
Table 38 Canada: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 39 Canada: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 40 Canada: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 41 Canada: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 42 Europe: Ubiquitous Pharmacogenomics Contributions (USD Million)
Table 43 Europe: Pharmacogenomics Market, by Country/Region, 2022–2031 (USD Million)
Table 44 Europe: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 45 Europe: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 46 Europe: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 47 Europe: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 48 Germany: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 49 Germany: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 50 Germany: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 51 Germany: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 52 France: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 53 France: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 54 France: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 55 France: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 56 U.K. Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 57 U.K. Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 58 U.K. Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 59 U.K. Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 60 Italy: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 61 Italy: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 62 Italy: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 63 Italy: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 64 Spain: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 65 Spain: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 66 Spain: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 67 Spain: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 68 Rest of Europe: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 69 Rest of Europe: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 70 Rest of Europe: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 71 Rest of Europe: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 72 Asia-Pacific: Pharmacogenomics Market, by Country/Region, 2022–2031 (USD Million)
Table 73 Asia-Pacific: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 74 Asia-Pacific: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 75 Asia-Pacific: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 76 Asia-Pacific: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 77 China: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 78 China: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 79 China: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 80 China: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 81 Japan: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 82 Japan: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 83 Japan: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 84 Japan: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 85 India: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 86 India: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 87 India: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 88 India: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 89 Rest of Asia-Pacific: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 90 Rest of Asia-Pacific: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 91 Rest of Asia-Pacific: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 92 Rest of Asia-Pacific: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 93 Latin America: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 94 Latin America: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 95 Latin America: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 96 Latin America: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 97 Middle East & Africa: Pharmacogenomics Market, by Offering, 2022–2031 (USD Million)
Table 98 Middle East & Africa: Pharmacogenomics Market, by Technology, 2022–2031 (USD Million)
Table 99 Middle East & Africa: Pharmacogenomics Market, by Application, 2022–2031 (USD Million)
Table 100 Middle East & Africa: Pharmacogenomics Market, by End User, 2022–2031 (USD Million)
Table 101 Recent Developments, by Company (2020–2023)
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Pharmacogenomics Market, by Offerings, 2024 Vs. 2031 (USD Million)
Figure 8 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 9 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 10 Global Pharmacogenomics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 11 Global Pharmacogenomics Market, by Geography
Figure 12 Impact Analysis of Market Dynamics
Figure 13 Percentage Share of U.S. FDA-Approved PGx-Labeled Drugs, by Application (As of June 2023)
Figure 14 U.S.: Number of Personalized Medicines on The Market, 2008-2020
Figure 15 Molecular and Cell-Based Therapies (As a Percentage of Total FDA-Approved Therapies), 2015-2021
Figure 16 Global Estimated Number of New Cancer Cases, 2020-2040 (In Million)
Figure 17 Genome Sequencing Costs, 2010–2022 (USD)
Figure 18 USFDA Regulatory Pathways for Pharmacogenomics Products
Figure 19 EU Regulatory Pathway - IVDR 2017/746
Figure 20 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
Figure 21 Porter’s Five Forces Analysis
Figure 22 Global Pharmacogenomics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 23 Global Estimated Number of New Cancer Cases (2020-2040) (Million)
Figure 24 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 25 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 26 Estimated Number of New Cancer Cases, 2020 Vs. 2040
Figure 27 Global Pharmacogenomics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 28 Global Pharmacogenomics Market Assessment, by Country/Region, 2024–2031 (USD Million)
Figure 29 North America: Pharmacogenomics Market Snapshot
Figure 30 Precision Medicine Research Funding To NIH, 2018-2024 (USD Million)
Figure 31 Europe: Pharmacogenomics Market Snapshot
Figure 32 Germany: Estimated Number of New Cancer Cases, 2020-2035 (In Thousand)
Figure 33 France: Total Number of People with Dementia, 2018-2050 (In Thousands)
Figure 34 Asia-Pacific: Pharmacogenomics Market Snapshot
Figure 35 Key Growth Strategies Adopted by Leading Market Players (2020-2023)
Figure 36 Pharmacogenomics Market: Competitive Benchmarking, by Offering
Figure 37 Pharmacogenomics Market: Competitive Benchmarking, by Region
Figure 38 Competitive Dashboard: Pharmacogenomics Market
Figure 39 Global Pharmacogenomics Market Ranking, by Key Players (2023)
Figure 40 F. Hoffmann La-Roche Ltd.: Financial Snapshot (2022)
Figure 41 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 42 Illumina, Inc.: Financial Overview (2022)
Figure 43 Danaher Corporation: Financial Overview (2022)
Figure 44 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 45 Qiagen N.V.: Financial Snapshot (2022)
Figure 46 Abbott Laboratories: Financial Overview (2022)
Figure 47 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
Figure 49 Pacific Biosciences of California, Inc.: Financial Overview (2022)
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe DTC Laboratory Testing Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific DTC Laboratory Testing Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Europe Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2024 -2030)
Published Date: Jul-2024
